Abstract
In esophageal neoplasms, the histopathologic differentiation between Barrett’s esophagus with or without intraepithelial neoplasia and adenocarcinoma is often challenging. Immunohistochemistry might help to differentiate between these lesions. The expression of CDX2, LI-cadherin, mucin 2 (MUC2), blood group 8 (BG8, Lewisy), claudin-2, and villin was investigated in normal gastroesophageal (n = 23) and in Barrett’s (n = 17) mucosa, in low-grade (n = 12) and high-grade (n = 9) intraepithelial neoplasia (IEN) as well as in esophageal adenocarcinoma (n = 16), using immunohistochemistry. For CDX2 and LI-cadherin, the immunoreactivity score was highest in IEN while for MUC2, BG8, and villin, it dropped gradually from Barrett’s via IEN to adenocarcinoma, and expression of Claudin-2 was only weak and focal in all lesions. The expression of MUC2 and LI-cadherin differed significantly between all examined lesions except between low-grade and high-grade IEN. MUC2 and LI-cadherin are useful immunohistochemical markers for the differentiation between normal glandular mucosa, Barrett’s mucosa, IEN, and invasive carcinoma of the esophagus; however, none of the examined markers was helpful for the differentiation between low-grade and high-grade IEN.
Similar content being viewed by others
References
Barrett NR (1950) Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 38:175–182
Barrett NR (1957) The lower esophagus lined by columnar epithelium. Surgery 41:881–894
Haggitt RC (1992) Adenocarcinoma in Barrett’s esophagus: a new epidemic? Hum Pathol 23:475–476
Sarosi G, Brown G, Jaiswal K et al (2008) Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis Esophagus 21:43–50
Sampliner RE (1998) Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’sesophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 93:1028–1032
Weinstein WM, Ippoliti AF (1996) The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest Endosc 44:91–95
Batts KP (2001) Barrett esophagus—more steps forward. Hum Pathol 32:357–359
Goldblum JR (2003) Barrett’s esophagus and Barrett's-related dysplasia. Mod Pathol 16:316–324
Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289
Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99:860–868
Eloubedi MA, Provenzale D (1999) Does this patient have Barrett’s esophagus? The utility of predicting Barrett’s esophagus at the index endoscopy. Am J Gastroenterol 94:937–943
Freund JN, Domon-Dell C, Kedinger M, Duluc I (1998) The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol 76:957–969
Suh E, Traber PG (1996) An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol 16:619–625
Eda A, Osawa H, Yanaka I, Satoh K, Mutoh H, Kihira K, Sugano K (2002) Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol 37:94–100
Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, Mutoh H, Sugano K (2003) Aberrant expression of CDX2 in Barrett’sepithelium and inflammatory esophageal mucosa. J Gastroenterol 38:14–22
Ko S, Chu KM, Luk JM, Wong BW, Yuen ST, Leung SY, Wong J (2005) CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol 205:615–622
Ranscht B (1994) Cadherins and catenins: interactions and functions in embryogenic development. Curr Opin Cell Biol 6:740–746
Takeichi M (1995) Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 7:619–627
Takeichei M (1993) Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5:806–811
Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153:333–339
Berndorff D, Gessner R, Kreft B, Schnoy N, Lajous-Petter AM, Loch N, Reutter W, Hotsch M, Tauber R (1994) Liver–intestine cadherin: molecular cloning and characterization of a novel Ca2+-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol 125:1353–1369
Gessner R, Tauber R (2000) Intestinal cell adhesion molecules. Liver–intestine cadherin. Ann NY Acad Sci 915:136–143
Hinoi T, Lucas PC, Kuick R, Hanash S, Cho KR, Fearon ER (2002) CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology 123:1565–1577
Grötzinger C, Kneifel J, Patschan D, Schnoy N, Anagnostopoulos I, Faiss S, Tauber R, Wiedenmann B, Gessner R (2001) LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 49:8
Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, Fan ST (2003) Identification of liver–intestine cadherin in hepatocellular carcinoma—a potential disease marker. Biochem Biophys Res Commun 311:618–624
Takamura M, Sakamoto M, Ino Y, Shimamura T, Ichida T, Asakura H, Hirohashi S (2003) Expression of liver–intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci 94:425–430
Fitzgerald RC, Omary MB, Triadafilopoulos G (1997) Acid modulation of HT29 cell growth and differentiation: an in vitro model for Barrett’s esophagus. J Cell Sci 110:663–671
Niwa T, Ikehara Y, Nakanishi H et al (2005) Mixed gastric- and intestinal-type metaplasia is formed by cells with dual intestinal and gastric differentiation. J Histochem Cytochem 53:75–85
Dudouet B, Robine S, Huet C et al (1987) Changes in villin synthesis and subcellular distribution during intestinal differentiation of HT29-18 clones. J Cell Biol 105:359–369
Furuse M, Sasaki H, Tsukita S (1999) Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 147:891–903
Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, Chiba H (2003) Tight junctions and human diseases. Med Electron Microsc 36:147–156
Offner S, Hekele A, Teichmann U, Weinberger S, Gross S, Kufer P, Itin C, Baeuerle PA, Kohleisen B (2004) Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunother 54:431–445
Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678–684
Ho SB, Niehans GH, Lyftogt C, Yan PS, Cherwitz DL et al (1993) Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53:641–651
Burjonrappa SC, Reedimasu S, Nawaz Z et al (2009) Mucin expression profile in Barrett´s, dysplasia, adenocarcinoma sequence in the esophagus. Indian J Cancer 44:1–5
Blaszczyk-Thurin M, Ramachandran M, Westerink MAJ et al (1996) Molecular recognition of the Lewis Y antigen by monoclonal antibodies. Prot Engineering 5:447–459
Werner M, Flejou JF, Hainaut P, Hoefler H, Lambert R, Keller G, Stein HJ (2000) Adenocarcinoma of the oesophagus. In: Hamilton SR, Aaltonen LA (eds) WHO classification of tumours, pathology & genetics, tumors of the digestive system. IARC Press, Lyon, pp 20–26
Weimann A, Zimmermann M, Gross M, Slevogt H, Rieger A, Morawietz L (2010) CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma. Int J Surg Pathol. doi:10.1177/1066896910364428
Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140
Conio M, Lapertosa G, Blanchi S, Filiberti R (2003) Barrett’s esophagus: an update. Crit Rev Oncol Hematol 46:187–206
Falk GW (2002) Barrett’s esophagus. Gastroenterology 122:1569–1591
Menke-Pluymers MB, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW (1994) Dysplasia and aneuploidy as markers of malignant degeneration in Barrett’s oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 35:1348–1351
Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS (2000) Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95:1669–1676
Ko S, Chu KM, Luk JM, Wong BW, Yuen ST, Leung SY, Wong J (2004) Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochem Biophys Res Commun 319:562–568
Phillips RW, Frierson HF Jr, Moskaluk CA (2003) Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 27:1442–1447
Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y (1989) Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol 20:53–57
Riera JR, Astengo-Osuna C, Longmate JA, Battifora H (1997) The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 21:1409–1419
Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA (1995) Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone: the need for surgical therapy re-emphasized. Ann Surg 222:525–531
Yamamoto H, Bai YQ, Yuasa Y (2003) Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 300:813–818
Yamamichi N, Inada KI, Furukawa C, Sakurai K et al (2009) Cdx2 and the Brm-type SWI/SNF complex cooperatively regulate villin expression in gastrointestinal cells. Exp Cell Res 315:1779–1789
Jovov B, Van Itallie CM, Shaheen NJ, Carson JL et al (2007) Claudin-18: a dominant tight junction protein in Barrett’s esophagus and likely contributor to its acid resistance. Am J Physiol Gastrointest Liver Physiol 293:1106–1113
Györffy H, Holczbauer A, Nagy P, Szabó Z et al (2005) Claudin expression in Barrett's esophagus and adenocarcinoma. Virchows Arch 447:961–968
Acknowledgments
The excellent technical assistance of Mrs. Gabriele Fernahl is gratefully acknowledged.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Andreas Weimann and Anja Rieger contributed equally to this work
Rights and permissions
About this article
Cite this article
Weimann, A., Rieger, A., Zimmermann, M. et al. Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett’s esophagus. Virchows Arch 457, 537–545 (2010). https://doi.org/10.1007/s00428-010-0972-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-010-0972-y